Could a form of vitamin B12 help control a rare liver disease?
NCT ID NCT05835505
First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This Phase 2 trial tests whether the drug BRS201 (a form of vitamin B12) can improve liver health in people with primary sclerosing cholangitis (PSC), a rare liver disease. Over 8 weeks, 28 participants will take either the drug or a placebo for 4 weeks each, in random order. The main goal is to see if BRS201 lowers a key liver enzyme called alkaline phosphatase, which is often high in PSC.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BRS201 (hydroxocobalamin, a form of vitamin B12)
- What this could lead to
- If it works, this could point toward a treatment to control liver damage in primary sclerosing cholangitis by lowering key liver enzyme levels.
- What could go wrong
- This is a small, early Phase 2 trial with only 28 people. It tests a short-term effect on a lab marker, not long-term outcomes, so results may not lead to a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGChestnut Hill, Massachusetts, 02467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?